Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
IPO Year: 2018
Exchange: NASDAQ
Website: motusgi.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/25/2023 | Buy → Neutral | Ladenburg Thalmann |
SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)
SC 13G - Motus GI Holdings, Inc. (0001686850) (Subject)
SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)
SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)
SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)
Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q
Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes a
Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi
FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS, or "Motus" or "the Company"))), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company's common stock for gross proceeds to the Company of approximately $2.7 million. As part of this transaction, the investor agreed to exercise the existing Series B common stock purchase warrant (which was originally issued in December 2023
FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. ("the "Company") (NASDAQ:MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, "Colon Cleaning System with Automatic Self-Purging Feature." "We are pleased to announce further strengthening our IP portfolio in the U.S. This latest patent covers the automated management of pressure for irrigation and self-purging feature of the latest generation of the Pure-Vu system. This capability is key to enhancing the physician's experience usin
FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. ("the Company") (NASDAQ:MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the "Special Meeting") was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on January 24, 2024 (the "Proxy Statement"). The adjourned Special Meeting will reconvene on March 7, 2024 at 9:30 a.m. Eastern Time at www.cstproxy.com/motusgi/sm2024. The original record date of December 20,
FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS, or "Motus GI" or "the Company"))), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the publication of positive data from a study of the second generation Pure-Vu System in a manuscript titled, "An intraprocedural bowel cleansing system for difficult-to-prepare patients—A multicenter prospective feasibility study," in the peer-reviewed journal, United European Gastroenterology (UGE). The Company's Pure-Vu System is an FDA-approved and CE-certified bowel cleansing system (BCS) intended to increase visualization in inadequately prepared colons b
FORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS, or "Motus GI" or "the Company"))), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the pricing of a public offering of 3,333,334 shares of common stock (or pre-funded warrants in lieu thereof), Series A common warrants to purchase up to 3,333,334 shares of common stock, and Series B common warrants to purchase up to 3,333,334 shares of common stock, at a combined public offering price of $1.50 per share (or pre-funded warrant in lieu thereof) and Series A common warrant and Series B common warrant, each to purchase one share of common stock,
- - -The upper GI procedure was performed by Dr. Brian Hanson, gastroenterologist and Assistant Professor, Medicine, at the University of Minnesota- - -Pure-Vu EVS Gastro addresses the Upper GI market, an area of high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. according to iData Research Inc. FORT LAUDERDALE, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that the Pure-Vu® EVS Gastro was successfully used in the first procedure since receiving FDA clearance. The case was
FORT LAUDERDALE, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it will effect a 1-for-15 reverse stock split of its outstanding common stock. The Company's common stock will begin trading on a split-adjusted basis at the opening of the market on Thursday, November 2, 2023. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "MOTS" and under the new CUSIP number: 62014P504. The reverse stock split is intended to increase the per share trading price of Motus GI's common stock to
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
3 - Motus GI Holdings, Inc. (0001686850) (Issuer)
3 - Motus GI Holdings, Inc. (0001686850) (Issuer)
3 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
Ladenburg Thalmann downgraded Motus GI from Buy to Neutral
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
15-12G - Motus GI Holdings, Inc. (0001686850) (Filer)
S-8 POS - Motus GI Holdings, Inc. (0001686850) (Filer)
S-8 POS - Motus GI Holdings, Inc. (0001686850) (Filer)
S-8 POS - Motus GI Holdings, Inc. (0001686850) (Filer)
S-8 POS - Motus GI Holdings, Inc. (0001686850) (Filer)
Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi
FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi
Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-rewa
Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers, including seeking key FDA approvals and pursuit of strategic partnerships to accelerate commercialization FORT LAUDERDALE, Fla., June 05, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today announced the promotion of its current Vice President of Global Operation and Finance, Ravit Ram, as the new Chief Financial Officer (CFO), effective immediately. Ms. Ram's appointment is part of the previously announced transition plan for Andrew
New company name chosen to represent focus on ‘averting' serious cardiac complications with state-of-the-art Guardian™ monitoring and alerting system President and CEO Tim Moran and Chief Financial Officer Philip Tom to join Executive Chairman Ross Haghighat in leadership roles EATONTOWN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Angel Medical Systems Inc. (dba AngelMed), a company focused on improving long-term management of high-risk coronary disease in patients who have survived one or more heart attacks, today announced it has changed its corporate name to Avertix Medical Inc. (Avertix), and appointed Tim Moran as President and Chief Executive Officer and Philip Tom as Executive Vice
Tim Moran transitions from Chief Executive Officer to Chairman of the Board and Mark Pomeranz appointed Chief Executive Officer to lead next phase of Company Restructuring plan reduces operating expenses by an additional ~25%, extending cash runway to support FDA submission of Pure-Vu Upper GI and fourth generation Lower GI product before the end of 2023 FORT LAUDERDALE, Fla. , April 13, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today announced executive changes and restructuring as part of its strategy to reduce operating costs while supporting key v
FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (NASDAQ:NK) an
Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q
The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueThe Company is actively supporting its existing installed customer base and pipeline opportunities in contracted health systems The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures, and expects submission to FDA by the end of 2023 FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and e
Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's historyRecently named a Sole Source Supplier by the Department of Veteran's Affairs, with several VA medical centers executing new contracts for Pure-Vu EVS systems under this designationPresented positive clinical data in three abstracts at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting that further illustrate how Pure-Vu EVS is enabling physicians to significantly improve visualization during colonoscopy procedures across different settings and patient populations FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSW
FORT LAUDERDALE, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its third quarter financial results on Monday, November 14, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments. Conference Call and Webcast Date and Time:Monday, November 14, 2022 at 4:3
Pure-Vu EVS approved for use at 18 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's history Expansion of U.S. commercial footprint successfully driving access to new hospitals and improving support for existing customers Announces upcoming ~1,000 patient, multi-center trial to support the Company's pursuit of outpatient reimbursement for the Pure-Vu EVS System FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnos
FORT LAUDERDALE, Fla., July 21, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter financial results on Thursday, August 11, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments. Conference Call and WebcastDate and Time:Thursday, August 11, 2022 at 4:30 p.m. ETDomestic:
Pure-Vu EVS approved for use at 11 hospitals since product launch commenced in March 2022; with strong procedural volumes and significant positive feedback Expansion of US commercial footprint ahead of schedule, with additional investments planned throughout 2022Designing a large, multi-center trial as part of the strategy to secure reimbursement for the Pure-Vu EVS System for certain outpatient colonoscopies FORT LAUDERDALE, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and ma
FORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter financial results on Thursday, May 12, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments. Conference Call and WebcastDate and Time: Thursday, May 12, 2022 at 4:30 p.m. ETDomestic: 844-
Received FDA clearance in February 2022 to market Pure-Vu EVS, an all new, next-generation system that has been deployed to multiple hospitals in the first few weeks since launch Doubled the size of the sales team since November, and plan to continue investing in commercial expansion throughout 2022 Advancing strategy to secure reimbursement for the Pure-Vu System for certain outpatient colonoscopies, targeting ~4.7M outpatient procedures per year in the U.S. FORT LAUDERDALE, Fla., March 29, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance
FORT LAUDERDALE, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and full year financial results on Tuesday, March 29, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments. Conference Call and WebcastDate and Time: Tuesday, March 29that 4:30 p.m. ETDo